share_log

Recursion Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Recursion Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Recursion Pharmaceuticals | S-8：員工福利計劃證券登記
美股sec公告 ·  05/10 15:06
Moomoo AI 已提取核心訊息
Recursion Pharmaceuticals, Inc., a biotechnology firm incorporated in Delaware, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on May 10, 2024. This filing pertains to the registration of additional shares of Class A common stock under the company's 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The registration builds upon previous filings made on April 16, 2021, May 10, 2022, and May 8, 2023. The company, which is classified as a large accelerated filer, has incorporated by reference its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and subsequent reports filed with the SEC. The documents incorporated by reference include detailed information about the company's financial performance and governance. The CEO, Christopher Gibson, along with other executives and directors, have signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
Recursion Pharmaceuticals, Inc., a biotechnology firm incorporated in Delaware, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on May 10, 2024. This filing pertains to the registration of additional shares of Class A common stock under the company's 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The registration builds upon previous filings made on April 16, 2021, May 10, 2022, and May 8, 2023. The company, which is classified as a large accelerated filer, has incorporated by reference its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and subsequent reports filed with the SEC. The documents incorporated by reference include detailed information about the company's financial performance and governance. The CEO, Christopher Gibson, along with other executives and directors, have signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
在特拉華州註冊的生物技術公司Recursion Pharmicals, Inc. 已於2024年5月10日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件涉及根據公司2021年股權激勵計劃和2021年員工股票購買計劃註冊額外A類普通股。該註冊建立在先前於2021年4月16日、2022年5月10日和2023年5月8日提交的申請基礎上。該公司被列爲大型加速申報人，已以引用方式納入了截至2023年12月31日財年的10-K表年度報告以及隨後向美國證券交易委員會提交的報告。以引用方式納入的文件包括有關公司財務業績和治理的詳細信息。首席執行官克里斯托弗·吉布森以及其他高管和董事簽署了註冊聲明，確認公司遵守了提交S-8表格的要求。
在特拉華州註冊的生物技術公司Recursion Pharmicals, Inc. 已於2024年5月10日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件涉及根據公司2021年股權激勵計劃和2021年員工股票購買計劃註冊額外A類普通股。該註冊建立在先前於2021年4月16日、2022年5月10日和2023年5月8日提交的申請基礎上。該公司被列爲大型加速申報人，已以引用方式納入了截至2023年12月31日財年的10-K表年度報告以及隨後向美國證券交易委員會提交的報告。以引用方式納入的文件包括有關公司財務業績和治理的詳細信息。首席執行官克里斯托弗·吉布森以及其他高管和董事簽署了註冊聲明，確認公司遵守了提交S-8表格的要求。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息